These UniCAR-T CD123 cells were evaluated in a phase I clinical trial (NCT 04230265) in relapsed/refractory AML patients with the aim of evaluating the safety profile and for obtaining preliminary data on clinical efficacy. The gene discussed is IL3RA; the disease is acute myeloid leukemia.